Pfizer pharmaceutical corporation and biotechnology company BioNTech have the production of their vaccine in order. They have already produced nearly 50 million doses for this year, the two companies say. This contradicts a message in business newspaper The Wall Street Journal that they would not make their production for this year through procurement problems.
According to The Wall Street Journal, Pfizer and BioNTech would have had to halve their production target for this year from 100 million doses to 50 million doses, but that happened at the beginning of November, BioNTech says. Among other things, the time schedule for approval the vaccine in several countries caused this.
Pfizer and BioNTech are thinking of delivering 1.3 billion doses of their SARSv2 vaccine to several countries next year. The two companies are looking at ways of increasing production even further.
Moderna announced that it could make 500 million doses of his vaccine next year. To double that, the company needs more resources, said CEO Stéphane Bancel. Whether it’s just about money or other things, he didn’t say.
Lesley Woutersen, one of the co-founders of the EconomicInform gives away all of his free time to the project. He is interested in stock exchange and digital assets. Lesley can be reached by lesley.woutersen@economicinform.com.
